Review: Side effects of approved molecular targeted therapies in solid cancers

被引:252
作者
Widakowich, Christian [1 ,2 ]
De Castro, Gilberto, Jr. [3 ]
De Azambuja, Evandro [1 ,2 ]
Dinh, Phuong [1 ]
Awada, Ahmad [1 ,2 ]
机构
[1] Inst Jules Bordet, Med Oncol Clin, Dept Med, B-1000 Brussels, Belgium
[2] Univ Libre Bruxelles, Brussels, Belgium
[3] Univ Sao Paulo, Sch Med, Hosp Clin, Clin Oncol Serv, Sao Paulo, Brazil
关键词
targeted therapy; toxicity; anti-EGFR agents; anti-HER-2; agents; anti-VEGFR agents;
D O I
10.1634/theoncologist.12-12-1443
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Major advances have been achieved in the field of biologically based therapies for cancer in the last few years, and some of the recently approved molecular-targeted therapies are now being used in daily clinical practice. These molecular targets are also expressed in normal cells, which explains the different grades of toxicity, resulting from the disruption of normal cellular function. In general, targeted molecular therapies have good toxicity profiles, but some patients are exquisitely sensitive to these drugs and can develop particular and severe toxicities. In this article, we review the toxicity and safety of various small molecules and monoclonal antibodies used in solid tumors, with discussion of the pathophysiology, correlation with response, and strategies for prevention and management.
引用
收藏
页码:1443 / 1455
页数:13
相关论文
共 113 条
[1]   Dermatologic side effects associated with the epidermal growth factor receptor inhibitors [J].
Agero, Anna Liza C. ;
Dusza, Stephen W. ;
Benvenuto-Andrade, Cristiane ;
Busam, Klaus J. ;
Myskowski, Patricia ;
Halpern, Allan C. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) :657-670
[2]   Kinase inhibition with BAY 43-9006 n renal cell carcinoma [J].
Ahmad, T ;
Eisen, T .
CLINICAL CANCER RESEARCH, 2004, 10 (18) :6388S-6392S
[3]   Role of Raf in vascular protection from distinct apoptotic stimuli [J].
Alavi, A ;
Hood, JD ;
Frausto, R ;
Stupack, DG ;
Cheresh, DA .
SCIENCE, 2003, 301 (5629) :94-96
[4]   Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors [J].
Alexandrescu, D. T. ;
Vaillant, J. G. ;
Dasanu, C. A. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2007, 32 (01) :71-74
[5]  
[Anonymous], SAN ANT BREAST CANC
[6]  
*ASTR ZEN, 2003, EXP COMM M REP FIN R
[7]   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].
Baselga, J ;
Pfister, D ;
Cooper, MR ;
Cohen, R ;
Burtness, B ;
Bos, M ;
D'Andrea, G ;
Seidman, A ;
Norton, L ;
Gunnett, K ;
Falcey, J ;
Anderson, V ;
Waksal, H ;
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914
[8]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
[9]  
Behr TM, 2001, NEW ENGL J MED, V345, P995
[10]   SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit [J].
Botchkareva, NV ;
Khlgatian, M ;
Longley, BJ ;
Botchkarev, VA ;
Gilchrest, BA .
FASEB JOURNAL, 2001, 15 (03) :645-658